



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/703,798	11/02/2000	Amanda Johanne Kiljaan	BO 44102 ACW	2164

466 7590 02/08/2002

YOUNG & THOMPSON
745 SOUTH 23RD STREET 2ND FLOOR
ARLINGTON, VA 22202

EXAMINER

DAVIS, RUTH A

ART UNIT	PAPER NUMBER
----------	--------------

1651

DATE MAILED: 02/08/2002

4

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)
	09/703,798	KILIAAN ET AL.
	Examiner Ruth A. Davis	Art Unit 1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on ____.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 1-18 is/are pending in the application.

4a) Of the above claim(s) ____ is/are withdrawn from consideration.

5) Claim(s) ____ is/are allowed.

6) Claim(s) 1-18 is/are rejected.

7) Claim(s) 12 and 16 is/are objected to.

8) Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on ____ is/are: a) accepted or b) objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) The proposed drawing correction filed on ____ is: a) approved b) disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.

12) The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some * c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. ____.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) The translation of the foreign language provisional application has been received.

15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). ____
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.	6) <input type="checkbox"/> Other: ____

DETAILED ACTION

Specification

1. The disclosure is objected to because of the following informalities: the term “gingko” should be correctly spelled “ginkgo” throughout the specification.

Appropriate correction is required.

Claim Objections

2. Claim 12 is objected to because of the following informalities: The term “gingko” should be spelled “ginkgo”. Appropriate correction is required.
3. Claim 16 is objected to because of the following informalities: In line 4, “vene” should be correctly spelled “vein”. Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claims 1 – 18 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 – 4, 10 – 12 and their dependents are drawn to a composition however are rendered vague and indefinite for the simultaneous use of two mutually exclusive transitional phrases, e.g. “comprising the following fractions” and “fraction (x) consisting of”. It is unclear what applicant intends to include and/or exclude from claimed invention because the two phrases define the composition with two separate, mutually exclusive, scopes.

Claim 1 and its dependents are rendered vague and indefinite for reciting “or equivalents thereof” because it is unclear what applicant regards as an “equivalent” of the instant ingredients. Moreover, applicant does not clearly set forth the scope of the limitation.

Claim 2 is rendered vague and indefinite for reciting “citrate or citric acid” because the two are the same. It is unclear why both names for the same compound are provided, as they are the same.

Claims 3 and 10 are rendered vague and indefinite for reciting “or functional analogs thereof” because it is unclear what is encompassed by the limitation of the claimed invention. Applicant does not define what is a “functional analog thereof”, therefore the claim is unclear and confusing.

Claims 4 and 5 are unclear for reciting “Ω”. Applicant may prefer to replace “Ω” with “omega” to more clearly define the invention.

Claim 9 is rendered vague and indefinite because it is unclear if fraction c) rather comprises zinc and copper in a ratio between 5 – 12, or further comprises zinc and copper in a ratio between 5 – 12.

Claim 10 is rendered vague and indefinite because it is unclear if “functional analogs thereof” refers only to coenzyme Q10, or to each carnitine, vitamin B1, B5 and coenzyme Q10.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74 (Bd. App. 1961); *Ex parte Hall*, 83 USPQ 38 (Bd. App. 1948); and *Ex parte Hasche*, 86 USPQ 481 (Bd. App. 1949).

In the present instance, claim 14 recites the broad recitations “at least X”, and the claim also recites “preferably at least Y” which are the narrower statements of the range/limitations.

Claim 16 is vague and indefinite for reciting “cerebrovascular accidents” and “temporary disorders associated with ischemia” because the claim language and specification fail to define the phrases.

Claim Rejections - 35 USC § 103

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

7. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

8. Claims 1, 4 – 7 and 15 – 18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami Chem Res Centre (1998), Horrobin (1996) and Hashim (1995).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine and (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc. The fatty acids are omega-3 and omega-6 fatty acids wherein the omega 3 fatty acids are selected from eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and the omega-6 fatty acids are selected from arachidonic

acid (ARA) and dihomogamma linolenic acid (DGLA). The phospholipids comprise phosphatidylcholine, phosphatidylethanolamine and phosphatidylserine. The fraction c) further comprises folic acid, vitamin B6 and SAMe, choline, betaine and/or copper. The composition treats and/or prevents vascular disorders or secondary disorders associated therewith, wherein vascular disorders are selected from atherosclerosis, arteriosclerosis, hypercholesterolemia, hyperlipidemia, elevated blood pressure, angina pectoris, dementia syndromes, cerebrovascular accidents, temporary disorders associated with ischaemia, M. Raynaud, vein thrombosis, postpartum thrombosis, myocard infact, varicose veins, thrombosis angiitis obliterans and atherosclerosis obliterans and secondary vascular disorders are dementia syndromes, cognitive degeneration or hearing loss. Finally, the composition is a nutritional supplement.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the

art for their claimed purpose. Although the references do not specifically teach the compositions treat secondary disorders associated with vascular disorders, by treating and/or preventing vascular disorders, one would effectively be treating/preventing secondary disorders. In addition, it would have been obvious to one of ordinary skill in the art to prepare the composition as a nutritional supplement because it was routine practice to do so in the art at the time the claimed invention was made. Moreover, at the time of the invention, one of ordinary skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

9. Claims 1 – 2 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami (1998), Horrobin (1996), Hashim (1995) and Sauvage et al. (US5401730).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine, (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc and (d) citrate/citric acid. Specifically, the composition comprises at least 120 mg long chain fatty acids, 200 mg phospholipids, 200 micrograms folic acid, and 500 mg citrate.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

Sauvage teaches compositions for treating thrombus formation, atherosclerosis and cardiovascular diseases comprising citric acid (abstract). The composition is disclosed to exhibit synergistic effects in inhibiting platelet aggregation (abstract).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the art for their claimed purpose. Moreover, at the time of the invention, one of ordinary

skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. Although the references do not teach the specific amounts as claimed, it would have been obvious to one of ordinary skill in the art to optimize volumes of effective ingredients as it was routine practice in the art at the time the claimed invention was made. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

10. Claims 1 and 3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami (1998), Horrobin (1996), Hashim (1995) and Murray (1997).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol,

phosphatidylcholine and phosphatidylethanolamine, (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc, and a fraction comprising huperzine A.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

Murray teaches compositions for treating vascular disease and myocarditis comprising huperzine (abstract).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the art for their claimed purpose. Moreover, at the time of the invention, one of ordinary skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

11. Claims 1 and 7 – 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami (1998), Horrobin (1996), Hashim (1995), Bland (US 5922704) and Cavazza et al. (US 5753703).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine and (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc. Specifically, the composition contains both folic acid and vitamin B6 as well as SAMe, choline, betaine and/or copper. The weight ratio of zinc to copper is between 5 – 12. The composition additionally comprises one or more selected from carnitine, vitamin B1, B5 and coenzyme Q10 and one or more antioxidants selected from vitamin C, E, lipoic acid, selenium salt and carotenoids.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

Bland teaches nutritional supplements comprising omega 3 and omega 6 fatty acids, magnesium, zinc, copper and selenium (abstract). Specifically, Bland teaches that the fatty acids are useful for maintaining cardiovascular health and cholesterol levels (col.2 line28-32). Bland further teaches that magnesium (col.2 line 49-56), zinc, copper (col.2 line 62-68), vitamins B6, B12, folate (folic acid) (col.3 line20-29), vitamins C, B1 and E (col.3 line 35-40) are involved in maintaining cardiovascular health, function and support as well as effectively prevent/treat vascular disorders and cardiac risk. Finally, Bland teaches a ratio of zinc to copper of about 5:1 (abstract).

Cavazza et al. teaches compositions for treating and preventing lipid metabolism disorders and cardiovascular disorders comprising omega 3 fatty acids (DHA and EPA, see col.1 line10-16) and carnitine (abstract). Cavazza specifically teaches the compositions are useful for treating/preventing vascular disorders, atherosclerotic and thromboembolic disorders (col.1 line 15-20). In addition, Cavazza teaches a synergistic effect between carnitines and omega 3 fatty acids (col.5 line 5-10). Other vitamins and antioxidants are included in the compositions to include alpha-tocopherol (vitamin E), beta carotene, selenium, zinc and magnesium (col.6 line 55 – col.7 line 15).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the

art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the art for their claimed purpose. Moreover, at the time of the invention, one of ordinary skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

12. Claims 1 and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami (1998), Horrobin (1996), Hashim (1995), Yanai (1998) and He (2000).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol,

phosphatidylcholine and phosphatidylethanolamine, (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc and a fraction comprising ginkgo biloba extract.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

Yanai teaches compositions for treating vascular disorders, dementia syndromes, and hypertension comprising ginkgo extract (abstract). In addition, He teaches extracts of ginkgo are used to prevent and cure hyperlipidemia, arteriosclerosis and vascular diseases (abstract).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the art for their claimed purpose. Moreover, at the time of the invention, one of ordinary skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known

properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

13. Claims 1, 12 and 14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sagami (1998), Horrobin (1996), Hashim (1995), Yanai (1998), Bland (US 5922704) and Sauvage et al. (US 5401730).

Applicant claims a composition for treating and/or preventing vascular disorders, the composition comprising (a) long chain polyunsaturated fatty acids, (b) phospholipids selected from at least two of phosphatidylserine, phosphatidylinositol, phosphatidylcholine and phosphatidylethanolamine, (c) at least one of folic acid, vitamin B12, B6, magnesium or zinc and a fraction comprising ginkgo biloba extract. Specifically, the composition comprises at least 20 mg EPA, 50 mg DHA, 50 mg ARA, 200 mg phospholipids, 200 micrograms folic acid, 100 mg magnesium, 5 mg zinc, 2 mg vitamin B6, 2 micrograms vitamin B12 and 1g citrate.

Sagami teaches compositions for improving lipids in the blood, arteriosclerosis and vascular diseases comprising DHA, phosphatidylcholine, phosphatidyl ethanolamine and/or phosphatidylserine (abstract).

Horrobin teaches compositions for treating/preventing hypertension, coronary heart disease and peripheral vascular disease that are enriched with DGLA and ARA, EPA or DHA (abstract).

Hashim teaches compositions for preventing vascular disorders comprising vitamin B6, betaine, choline, vitamin B12 and folic acid (abstract).

Yanai teaches compositions for treating vascular disorders, dementia syndromes, and hypertension comprising ginkgo extract (abstract).

Bland teaches nutritional supplements comprising omega 3 and omega 6 fatty acids, magnesium, zinc, copper and selenium (abstract). Specifically, Bland teaches that the fatty acids are useful for maintaining cardiovascular health and cholesterol levels (col.2 line28-32). Bland further teaches that magnesium (col.2 line 49-56), zinc, copper (col.2 line 62-68), vitamins B6, B12, folate (folic acid) (col.3 line20-29), vitamins C, B1 and E (col.3 line 35-40) are involved in maintaining cardiovascular health, function and support as well as effectively prevent/treat vascular disorders and cardiac risk. Finally, Bland teaches a ratio of zinc to copper of about 5:1 (abstract).

Sauvage et al. teaches compositions for treating thrombus formation, atherosclerosis and cardiovascular diseases comprising citric acid (abstract). The composition is disclosed to exhibit synergistic effects in inhibiting platelet aggregation (abstract). Sauvage additionally teaches methods for reducing vascular disorders using the composition (abstract).

The above references do not teach all of the ingredients combined together in a single composition. However, it would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to combine the instant ingredients for their known benefit, as disclosed by the cited references above, since each is well known in the art for their claimed purpose. Moreover, at the time of the invention, one of ordinary skill in the art would have been motivated to combine the instant ingredients with a reasonable expectation for successfully obtaining a composition suitable for preventing and/or treating vascular disorders. Although the references do not teach the specific amounts as claimed, it would have been obvious to one of ordinary skill in the art to optimize volumes of effective ingredients as it was routine practice in the art at the time the claimed invention was made. This rejection is based on the well established proposition of patent law that no invention resides in combining old ingredients of known properties where the results obtained thereby are no more than the additive effect of the ingredients, *In re Sussman*, 1943 C.D. 518.

The idea for combining them flows logically from their having been used individually in the prior art. *In re Pinten*, 459 F.2d 1053, 173 USPQ 801 (CCPA 1972); *In re Susi*, 58 CCPA 1074, 1079-80; 440 F.2d 442, 445; 169 USPQ 423, 426 (1971); *In re Crockett*, 47 CCPA 1018, 1020-21; 279 F.2d 274, 276-277; 126 USPQ 186, 188 (1960).

Thus, the invention as a whole is *prima facie* obvious over the references, especially in the absence of evidence to the contrary.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruth A. Davis whose telephone number is 703-308-6310. The examiner can normally be reached on M-H (7:00-4:30); altn. F (7:00-3:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 703-308-4743. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Ruth A. Davis; rad
February 5, 2002



LEON B. LANFORD, JR.
PRIMARY EXAMINER